Affimed Cash on Hand 2014-2024 | AFMDQ
Affimed cash on hand from 2014 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Affimed Annual Cash on Hand
(Millions of US $) |
| 2023 |
$79 |
| 2022 |
$200 |
| 2021 |
$234 |
| 2020 |
$168 |
| 2019 |
$117 |
| 2018 |
$128 |
| 2017 |
$45 |
| 2016 |
$50 |
| 2015 |
$85 |
| 2014 |
$53 |
| 2013 |
$0 |
| 2012 |
$0 |
Affimed Quarterly Cash on Hand
(Millions of US $) |
| 2024-09-30 |
$27 |
| 2024-06-30 |
$38 |
| 2024-03-31 |
$54 |
| 2023-12-31 |
$79 |
| 2023-09-30 |
$106 |
| 2023-06-30 |
$131 |
| 2023-03-31 |
$167 |
| 2022-12-31 |
$200 |
| 2022-09-30 |
$225 |
| 2022-06-30 |
$252 |
| 2022-03-31 |
$191 |
| 2021-12-31 |
$234 |
| 2021-09-30 |
$234 |
| 2021-06-30 |
$268 |
| 2021-03-31 |
$290 |
| 2020-12-31 |
$168 |
| 2020-09-30 |
$114 |
| 2020-06-30 |
$102 |
| 2020-03-31 |
$97 |
| 2019-12-31 |
$117 |
| 2019-09-30 |
$85 |
| 2019-06-30 |
$99 |
| 2019-03-31 |
$108 |
| 2018-12-31 |
$128 |
| 2018-09-30 |
$43 |
| 2018-06-30 |
$57 |
| 2018-03-31 |
$68 |
| 2017-12-31 |
$45 |
| 2017-09-30 |
$49 |
| 2017-06-30 |
$54 |
| 2017-03-31 |
$57 |
| 2016-12-31 |
$50 |
| 2016-09-30 |
$55 |
| 2016-06-30 |
$66 |
| 2016-03-31 |
$85 |
| 2015-12-31 |
$85 |
| 2015-09-30 |
$67 |
| 2015-06-30 |
$73 |
| 2015-03-31 |
$42 |
| 2014-12-31 |
$53 |
| 2014-09-30 |
$60 |
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
